News & Blog

Tag Archives: FDA

Brain Tumor News From the 2015 American Society for Clinical Oncology Meeting

From May 29 – June 2, National Brain Tumor Society Research and Scientific Operations staff attended the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, one of the most important cancer research meetings of the year. Each year, we attend ASCO to learn about the latest research on emerging new treatments and get updates on […]

National Brain Tumor Society’s 2015 Legislative Agenda

To guide our public policy advocacy efforts each year, National Brain Tumor Society creates an annual “Legislative Agenda.” Our yearly Legislative Agenda reflects the larger strategy and goals of the Organization, and our activities in carrying out the agenda directly influences our ability to deliver on our mission of better treatments, and ultimately a cure, […]

Encouraging Results from Novocure Clinical Trial

Novocure, a company that creates medical devices to treat cancer, announced this weekend that their Novo-TTF-100A system (now being called Optune), in combination with temozolomide (also know as Temodar or TMZ), demonstrated improved survival in newly diagnosed glioblastoma multiforme (GBM) patients in a clinical trial, compared with temozolomide alone. The announcement was made at the […]